HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT-Reference-Cited by-同舟云学术

HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT

Published:2019-06-03 Issue:7 Volume:16 Page:679-682
ISSN:1672-7681
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Rodriguez-Barbosa Jose Ignacio^ORCID,Schneider Pascal,Weigert Andreas^ORCID,Lee Kyung-Mi^ORCID,Kim Tae-Jin,Perez-Simon Jose-Antonio,del Rio Maria-Luisa^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/s41423-019-0241-1.pdf

Reference15 articles.

1. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999).

2. Bossen, C. et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281, 13964–13971 (2006).

3. Rodriguez-Barbosa, J. I., Fernandez-Renedo, C., Moral, A. M. B., Buhler, L. & Del Rio, M. L. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway. Cell Mol. Immunol. 14, 497–510 (2017).

4. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670–679 (2003).

5. Bekiaris, V., Sedy, J. R., Macauley, M. G., Rhode-Kurnow, A. & Ware, C. F. The inhibitory receptor BTLA controls gammadelta T cell homeostasis and inflammatory responses. Immunity 39, 1082–1094 (2013).

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causal role of immune cells in IgA nephropathy: a mendelian randomization study;Renal Failure;2024-07-22

2. BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes;iScience;2024-07

3. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma;Med;2024-07

4. Targeting BTLA with the peptide inhibitor HVEM(14-39) – A new way to restore the activity of T cells in melanoma;Biomedicine & Pharmacotherapy;2024-06

5. HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function;Cellular Oncology;2024-05-29